Table 1 Epidemiological characteristics of the sample
T2DM isolatesa | TB isolatesb | Total | |
|---|---|---|---|
(n = 74) | (n = 74) | (n = 148) | |
Sex | |||
Male | 44(59%) | 40 (54%) | 84(57.4%) |
Female | 30 (41%) | 34 (45%) | 64(42.6%) |
Age | |||
Mean (± SD) | 50 (± 10) | 42 (± 15) | 47 (± 13) |
Country | |||
Georgia | 8 (10.8%) | 28 (37%) | 36 (24.3%) |
Mexico | 23 (31%) | 11 (14.8%) | 34 (23%) |
Moldova | 6 (8.1%) | 14 (18.9%) | 20 (13.5%) |
Belarus | 4 (5.4%) | 11 (14.8%) | 15 (10.1% |
Romania | 2 (2.7%) | 10 (13.5%) | 12 (8.1%) |
Peru | 11 (14.8%) | 0 (0.0%) | 11 (7.4%) |
Indonesia | 9 (12.1%) | 0 (0.0%) | 9 (6.1%) |
Spain | 8 (10.8%) | 0 (0.0%) | 8 (5.4%) |
Azerbaijan | 3 (4%) | 0 (0.0%) | 3 (2%) |
Resistance typec | |||
MR | 20 (27%) | 20 (27%) | 40 (27%) |
POL | 9 (12.1%) | 9 (12.1%) | 18 (12.1%) |
MDR | 31 (48.8%) | 31 (48.8%) | 62 (41.8%) |
XDR | 14 (18.9%) | 14 (18.9%) | 28 (18.9%) |
Drug-resistance | |||
Isoniazid | 58 (67.5%) | 55 (74.3%) | 113 (76.3%) |
Rifampicin | 50 (67.5%) | 53 (71.6%) | 103 (69.5%) |
Streptomycin | 21 (28.3%) | 42 (56.7%) | 63 (42.5%) |
Ethambutol | 27 (36.4%) | 37 (50%) | 64 (43.2%) |
Pyrazinamide | 27 (36.4%) | 24 (32.4%) | 51 (34.4%) |
Amikacin | 19 (25.6%) | 30 (40.5%) | 49 (33.1%) |
Fluoroquinolones | 16 (21.6%) | 17 (22.9%) | 33 (22.3%) |